AZD4017 and prednisolone ( DrugBank: Prednisolone, AZD-4017 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 75 | Cushing disease | 1 |
75. Cushing disease
Clinical trials : 203 / Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03111810 (ClinicalTrials.gov) | May 25, 2017 | 17/3/2017 | Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition | Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) | Iatrogenic Cushing's Disease | Drug: AZD4017 and prednisolone;Drug: Placebo Oral Tablet and prednisolone | University of Oxford | AstraZeneca | Completed | 18 Years | 60 Years | Male | 32 | Phase 2 | United Kingdom |